ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2691

A Novel CD123–CD11c– Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus

Satoshi Kubo1, Shingo Nakayamada1, Naoki Yunoue1, Maiko Yoshikawa1, Kunihiro Yamaoka1 and Yoshiya Tanaka2, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: B cells, Dendritic cells, flow cytometry and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants

Session Type: Abstract Submissions (ACR)

Background/Purpose

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overproduction of autoantibodies by B cells and breaking self-tolerance of T cells and dendritic cells (DCs). However, little is known about the relationship between these immune cells in the etiology of SLE. Here, we found a novel DC subset and investigated the interaction among immune cell subsets in SLE.

Methods

Peripheral blood mononuclear cells were obtained from 44 patients with SLE, 20 with rheumatoid arthritis (RA), and 8 healthy donors (HD). Circulating B cells, T cells and DCs were defined based on comprehensive flow cytometric analysis for human immune system termed ‘the Human Immunology Project’ by NIH/FOCIS.

Results

The proportion of central memory B cells, effector B cells, and plasmablasts was higher (p=0.04, p=0.001, respectively), whereas the proportion of IgM memory B cells was lower (p<0.001) in SLE, compared to HD and RA. For T cell subsets, the proportion of effector memory T cells was highest in SLE (p=0.04). For DCs which were defined as CD3–CD14–CD19–CD20–HLA-DRhi, the percentage of CD11c+ myeloid DCs significantly decreased in SLE (p<0.001), while that of CD123+ plasmacytoid DCs was comparable among SLE, HD and RA (p=0.48). Interestingly, DCs that expressed neither CD11c nor CD123 were detected exclusively in SLE but not in the control or RA (p<0.001). To assess pathological relevance of this double-negative DC subset in SLE, we calculated the Pearson product-moment correlation coefficient among immune cell subsets and also conducted correlation clustering analysis. Among them, Double-negative DCs characteristically clustered with the central memory B cells and plasmablasts, and was correlated positively with plasmablasts (p=0.04) and negatively with myeloid DCs (p<0.001) and plasmacytoid DCs (p=0.04). Furthermore, the percentage of double-negative DCs was correlated with scores of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the British Isles Lupus Assessment Group (BILAG) index in patients. In 13 patients with treatment-naive in this cohort, the percentage of double-negative DCs was correlated positively with scores of SLEDAI and BILAG index as well as serum anti-dsDNA antibody levels and negatively with CH50 levels.

Conclusion

These results suggest that a novel CD123–CD11c– DC subset characteristically increased in relation to central memory B cells and plasmablasts in patients with treatment-naïve SLE. Furthermore, the frequencies of novel DC subsets were correlated with scores of SLEDAI and BILAG and serum levels of anti-dsDNA antibody, indicating that this DC subset may contribute to disease activity and autoantibody production. Although further studies are required, our findings would shed light on the activation mechanism of autoantibody production through the interaction between a novel DC subset and central memory B cells/plasmablasts in SLE and could be potentially useful in the design of new therapeutic strategies.


Disclosure:

S. Kubo,
None;

S. Nakayamada,
None;

N. Yunoue,
None;

M. Yoshikawa,
None;

K. Yamaoka,
None;

Y. Tanaka,

BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie and Daiichi-Sankyo,

2,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD and Asahi Kasei,

5,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD and Asahi Kasei,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-cd123cd11c-dendritic-cell-subset-increased-in-relation-to-disease-activity-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology